Promising Results: Low-Dose IMC-2 Therapy Reduces Long-COVID Fatigue and Sleep Issues
Summary: Dogwood Therapeutics reported positive results for its low-dose IMC-2 antiviral therapy in patients with long-COVID. The study found that the low-dose treatment (valacyclovir 750 mg + celecoxib 200 mg twice daily) significantly reduced fatigue and sleep issues compared to a placebo. However, the high-dose treatment was less effective, possibly due to more gastrointestinal side effects. These results may help in planning larger phase 2 studies.
Key Takeaways:
-
Efficacy of Low-Dose Therapy: The low-dose IMC-2 therapy significantly improved fatigue and sleep problems in long-COVID patients, unlike the high-dose treatment which was less effective.
-
Future Research Potential: The study results lay the foundation for larger, multi-center phase 2 trials to further explore treatment options for long-COVID symptoms.
- Need for Long-COVID Treatments: No FDA-approved therapies exist for long-COVID, making IMC-2 a potential solution for persistent fatigue and sleep disturbances in patients.
The study involved 14-15 participants per group and was a double-blinded, placebo-controlled trial called BHC Study 202. Although the sample size was small, meaningful improvements in fatigue and sleep disruption were observed compared to those receiving placebo.
Dr. R. Michael Gendreau, chief medical officer of Dogwood Therapeutics, stated, “IMC-2 showed a strong reduction in fatigue, which was the primary goal of this trial. We aim to advance IMC-2 into phase 2 development and will share further updates soon.”